In the neuronal in vitro cell system GCase supplementation can revert α-synuclein aggregation induced by PFFs, suggesting that GCase expression alone can be effective to treat α-synucleinopathies independent of a GBA1 mutation status. This evidence concerns the gene SNCA and synucleinopathy.